Recruiting
Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.
ClinicalTrials.gov IDNCT07713056
PhaseNot Applicable
Enrollment11
SponsorZhongnan Hospital
Age16 Years
SexALL
Conditions studied
Pigmentary Glaucoma
About this study
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.
Interventions
- Procedure: Ab-interno 120° Trabeculotomy — A minimally invasive glaucoma surgery (MIGS) procedure performed via an ab interno approach, involving a 120-degree incision of the trabecular meshwork to improve aqueous humor outflow.
Primary outcomes
- Change in Intraocular Pressure (IOP) at 6 Months Postoperatively (6 months postoperatively)
- Change in the Number of Intraocular Pressure-Lowering Medications at 6 Months (6 months postoperatively)
Eligibility information
Inclusion Criteria:
* Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects;
* Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment;
* Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements;
* Able to complete regular follow-up for at least 6 months postoperatively.
Exclusion Criteria:
* Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma;
* Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment;
* Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation;
* Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up;
* Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.
Study locations
- Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-29.